Le Lézard
Classified in: Health, Business
Subject: CON

Apotex Focuses on High Growth Markets with Sale of European Generics Business



Sale Part of Previously Announced Plan to Assess Global Footprint

TORONTO, July 14, 2018 /CNW/ - Apotex, Canada's largest generic pharmaceutical company, has signed an agreement to sell its commercial operations and certain supporting infrastructure for its generics business in five European countries to Aurobindo Pharma Limited.  The sale will allow Apotex to focus its resources on the Americas where strong demand for its portfolio continues.

"This is a positive move for our organization and enables us to further accelerate our efforts to drive additional growth in the Americas, while also creating manufacturing capacity to meet growing demand," said Jeff Watson, President & Chief Operating Officer, Apotex.

Apotex operates its European generic pharmaceutical business through wholly-owned subsidiaries in the Netherlands, Poland, the Czech Republic, Spain and Belgium.  Pursuant to the Agreement, these subsidiaries will be sold and certain supporting infrastructure including personnel, products, marketing authorizations and dossier license rights regarding the pharmaceutical business in those countries will effectively be transferred to Aurobindo Pharma Limited, once all closing conditions, which include customary competition clearance, are satisfied.

As part of the agreement, Apotex also entered into a transitional manufacturing and supply arrangement in order to support the ongoing growth plans of these businesses.

Apotex is a Canadian based, global pharmaceutical company, employing over 10,000 people in research, development, manufacturing and distribution facilities worldwide. Apotex is a vertically integrated business that includes generic medicines, biosimilars, active pharmaceutical ingredients and innovative pharmaceuticals. It produces more than 300 generic molecules in approximately 4,000 different dosages. For more information, please visit http://www.apotex.com

SOURCE Apotex Inc.


These press releases may also interest you

at 22:00
Amstar announces the appointment of Matthew Karp, Christopher Zeuner and Erin Little where the three will oversee investments and operations in the Americas and Europe.  Jason Lucas, Amstar's current President, will step down from his role at the end...

at 21:56
TSX VENTURE COMPANIES CLEAR BLUE TECHNOLOGIES INC. ("CBLU")BULLETIN TYPE:  New Listing-Shares, CorrectionBULLETIN DATE:  July 18, 2018TSX Venture Tier 2 Company Further to the bulletin dated July 17, 2018 whereby the common shares of the Company...

at 21:47
AJC is deeply disappointed that the Israeli Knesset, with the active support of Prime Minister Netanyahu, adopted today the controversial nation-state bill. The measure passed the 120-member Knesset by a vote of 62 to 55, with two abstaining. It will...

at 21:43
Natcore Technology Inc.  has announced its intent to raise CDN$195,000 via a non-brokered private placement. The placement involves the sale of up to 1,500,000 units at a price of CDN$0.13 per unit. Each unit comprises one common share and one share...

at 21:36
Kyligence, a leading data analytics company, today announced that the company has closed $15 million in Series B funding. This round was led by new investor Eight Roads Ventures (the proprietary investment arm of Fidelity International Limited) along...

at 21:28
CI Financial Corp. ("CI") announced today that it has entered into an agreement to sell debt securities with an aggregate principal amount of $325 million. The debt securities have a term of 5 years and carry an interest rate of 3.520% payable...




News published on 14 july 2018 at 01:00 and distributed by: